Synthesis and initial preclinical evaluation of the P2X7 receptor antagonist [¹¹C]A-740003 as a novel tracer of neuroinflammation.

Neuroinflammation, in particular activation of microglia, is thought to play an important role in the progression of neurodegenerative diseases. In activated microglia, the purinergic P2X7 receptor is upregulated. A-740003, a highly affine and selective P2X7 receptor antagonist, is a promising candidate for the development of a radiotracer for imaging of neuroinflammation by positron emission tomography. For this purpose, [(11)C]A-740003 was synthesised and evaluated in vivo with respect to both tracer metabolism and biodistribution. In plasma, a moderate metabolic rate was seen. In healthy rat brain, only marginal uptake of [(11)C]A-740003 was observed and, therefore, metabolites in brain could not be determined. Whether the minimal brain uptake is due to the low expression levels of the P2X7 receptor in healthy brain or to limited transport across the blood-brain barrier has yet to be elucidated.

[1]  Jans H. Alzate-Morales,et al.  Synthesis, in silico, in vitro, and in vivo investigation of 5-[¹¹C]methoxy-substituted sunitinib, a tyrosine kinase inhibitor of VEGFR-2. , 2012, European journal of medicinal chemistry.

[2]  R. Mach,et al.  Synthesis, radiolabeling and initial in vivo evaluation of [(11)C]KSM-01 for imaging PPAR-α receptors. , 2012, Bioorganic & medicinal chemistry letters.

[3]  H. Knölker,et al.  Transition metals in organic synthesis. Part 101: Convergent total synthesis of 1,6-dioxygenated carbazole alkaloids , 2012 .

[4]  Bertrand Tavitian,et al.  Noninvasive molecular imaging of neuroinflammation , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  M. Tsuda,et al.  Purinergic systems, neuropathic pain and the role of microglia , 2012, Experimental Neurology.

[6]  A. Brownell,et al.  Radiosynthesis of PET radiotracer as a prodrug for imaging group II metabotropic glutamate receptors in vivo. , 2012, Bioorganic & medicinal chemistry letters.

[7]  A. Bhattacharya,et al.  The physiology, pharmacology and future of P2X7 as an analgesic drug target: hype or promise? , 2011, Current pharmaceutical biotechnology.

[8]  P. Hayter,et al.  Receptor localization, native tissue binding and ex vivo occupancy for centrally penetrant P2X7 antagonists in the rat , 2011, British journal of pharmacology.

[9]  G. Burnstock,et al.  Microglia: proliferation and activation driven by the P2X7 receptor. , 2010, The international journal of biochemistry & cell biology.

[10]  M. Kassiou,et al.  P2X purinergic receptor ligands: recently patented compounds , 2010, Expert opinion on therapeutic patents.

[11]  Fred H. Gage,et al.  Mechanisms Underlying Inflammation in Neurodegeneration , 2010, Cell.

[12]  S. Sugama,et al.  P2X7 Receptor Signaling Pathway as a Therapeutic Target for Neurodegenerative Diseases , 2010, Archivum Immunologiae et Therapiae Experimentalis.

[13]  F. Berardi,et al.  Synthesis and preclinical evaluation of novel PET probes for P-glycoprotein function and expression. , 2009, Journal of medicinal chemistry.

[14]  L. Mortelmans,et al.  Synthesis and biological evaluation of (11)C-labeled beta-galactosyl triazoles as potential PET tracers for in vivo LacZ reporter gene imaging. , 2009, Bioorganic & medicinal chemistry.

[15]  Ying Wang,et al.  Discovery and biological evaluation of novel cyanoguanidine P2X(7) antagonists with analgesic activity in a rat model of neuropathic pain. , 2009, Journal of medicinal chemistry.

[16]  L. Alcaraz,et al.  Antagonists of the P2X(7) receptor. From lead identification to drug development. , 2009, Journal of medicinal chemistry.

[17]  Jinguo Huang,et al.  Synthesis and biological studies of inducible DNA cross-linking agents. , 2007, Angewandte Chemie.

[18]  M. Faul,et al.  A simple method for chemoselective phenol alkylation , 2007 .

[19]  Steven Whitebread,et al.  ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: identification, in vitro pharmacology, pharmacokinetic and biodistribution studies. , 2007, Bioorganic & Medicinal Chemistry.

[20]  D. Donnelly-roberts,et al.  A-740003 [N-(1-{[(Cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a Novel and Selective P2X7 Receptor Antagonist, Dose-Dependently Reduces Neuropathic Pain in the Rat , 2006, Journal of Pharmacology and Experimental Therapeutics.

[21]  Theodora W. Greene,et al.  Greene's Protective Groups in Organic Synthesis , 2006 .

[22]  Yves P Auberson,et al.  Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  P. Anand,et al.  COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord , 2006, BMC neurology.

[24]  A. Kozikowski,et al.  Methoxyphenylethynyl, methoxypyridylethynyl and phenylethynyl derivatives of pyridine: synthesis, radiolabeling and evaluation of new PET ligands for metabotropic glutamate subtype 5 receptors. , 2005, Nuclear medicine and biology.

[25]  E. Meggers,et al.  An extremely stable and orthogonal DNA base pair with a simplified three-carbon backbone. , 2005, Journal of the American Chemical Society.

[26]  H. Ohashi,et al.  Characterization with [3H]quisqualate of group I metabotropic glutamate receptor subtype in rat central and peripheral excitable tissues , 2001, Neurochemistry International.

[27]  A. Banerji,et al.  Low-valent titanium : A new approach to deprotection of allyl and benzyl groups , 1992 .